[go: up one dir, main page]

AR057222A1 - Agonistas del receptor del neuropeprtido -2 - Google Patents

Agonistas del receptor del neuropeprtido -2

Info

Publication number
AR057222A1
AR057222A1 ARP060105368A ARP060105368A AR057222A1 AR 057222 A1 AR057222 A1 AR 057222A1 AR P060105368 A ARP060105368 A AR P060105368A AR P060105368 A ARP060105368 A AR P060105368A AR 057222 A1 AR057222 A1 AR 057222A1
Authority
AR
Argentina
Prior art keywords
receptor agonists
neuropeprtido
neuropeptide
obesity
diabetes
Prior art date
Application number
ARP060105368A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057222(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR057222A1 publication Critical patent/AR057222A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan agonistas del receptor del neuropéptido-2- de formula (1): así como las sales farmacéuticamente aceptables, derivados y fragmentos del mismo, en el que los sustituyentes son tal y como se describen en la especificacion. Estos compuestos, y las composiciones farmacéuticas que los contienen, son utiles para el tratamiento de enfermedades como, por ejemplo, la obesidad y la diabetes.
ARP060105368A 2005-12-07 2006-12-05 Agonistas del receptor del neuropeprtido -2 AR057222A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74807105P 2005-12-07 2005-12-07
US85524906P 2006-10-30 2006-10-30

Publications (1)

Publication Number Publication Date
AR057222A1 true AR057222A1 (es) 2007-11-21

Family

ID=37964711

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105368A AR057222A1 (es) 2005-12-07 2006-12-05 Agonistas del receptor del neuropeprtido -2

Country Status (18)

Country Link
US (2) US7642244B2 (es)
EP (1) EP1962959B1 (es)
JP (1) JP5000663B2 (es)
KR (1) KR101059602B1 (es)
AR (1) AR057222A1 (es)
AT (1) ATE549350T1 (es)
AU (1) AU2006324076A1 (es)
BR (1) BRPI0619573A2 (es)
CA (1) CA2630649A1 (es)
EC (1) ECSP088511A (es)
ES (1) ES2381497T3 (es)
IL (1) IL191636A (es)
MA (1) MA30142B1 (es)
NO (1) NO20082445L (es)
NZ (1) NZ568772A (es)
RU (2) RU2430108C2 (es)
TW (1) TWI321474B (es)
WO (1) WO2007065808A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010069242A (ko) * 2000-09-05 2001-07-25 양우용 저주파 물리치료 겸용 혈압 강하기
NZ568772A (en) * 2005-12-07 2010-05-28 Hoffmann La Roche Truncated analogs of the peptide pYY3-36 that are neuropeptide-2 receptor-agonists
US8299023B2 (en) * 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
JP2012507487A (ja) * 2008-11-05 2012-03-29 エフ．ホフマン−ラ ロシュ アーゲー 神経ペプチド２受容体（ｙ−２ｒ）アゴニスト及びその使用
EP2450374B9 (en) 2009-07-02 2016-11-23 Takeda Pharmaceutical Company Limited Peptide and use thereof
EP2477643A1 (en) * 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
CA2776302A1 (en) * 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor (y-2r) agonists
RS60321B1 (sr) 2010-12-16 2020-07-31 Novo Nordisk As Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline
MX2013007559A (es) * 2011-01-03 2013-07-29 Hoffmann La Roche Composicion farmaceutica de complejo de anticuerpo anti-digoxigenina y digoxigenina que se conjuga a un peptido.
LT2827885T (lt) 2012-03-22 2018-10-10 Novo Nordisk A/S Glp-1 peptidų kompozicijos ir jų gavimas
RU2017128512A (ru) 2012-07-04 2019-02-15 Ф. Хоффманн-Ля Рош Аг Антитела к теофиллину и способы их применения
MX354303B (es) 2012-07-04 2018-02-23 Hoffmann La Roche Anticuerpos de anti-biotina y metodos de uso.
HUE030858T2 (en) 2012-07-04 2017-06-28 Hoffmann La Roche Covalently linked antigen-antibody conjugates
RU2671406C2 (ru) 2013-05-02 2018-10-31 Ново Нордиск А/С Пероральная дозированная форма соединений глюкагоноподобного пептида-1
EP3068795B1 (en) 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35
AU2014350197B2 (en) 2013-11-15 2018-10-04 Novo Nordisk A/S Selective PYY compounds and uses thereof
RU2693438C2 (ru) 2014-01-03 2019-07-02 Ф. Хоффманн-Ля Рош Аг Биспецифичные антитела против гаптена/против рецептора гематоэнцефалического барьера, их комплексы и их применение в качестве челноков гематоэнцефалического барьера
EP3089759B1 (en) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Covalently linked polypeptide toxin-antibody conjugates
WO2015101587A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
MA41898A (fr) * 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
AR104984A1 (es) 2015-06-12 2017-08-30 Novo Nordisk As Compuestos selectivos para pyy y sus usos
HUE063787T2 (hu) 2018-02-02 2024-01-28 Novo Nordisk As Egy GLP-1 agonistát, egy N-(8-(2-hidroxibenzoil)amino) kaprilsav sót és egy síkosítóanyagot tartalmazó szilárd készítmények
JOP20220110A1 (ar) 2019-11-11 2023-01-30 Boehringer Ingelheim Int ناهضات مستقبل npy2
MX2023001532A (es) 2020-08-07 2023-03-08 Boehringer Ingelheim Int Agonistas del receptor npy2 solubles.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
KR960701653A (ko) * 1993-03-29 1996-03-28 발라수브라마니암 엠비카이파칸 펩타이드 yy의 유사체 및 그의 용도
AUPO029096A0 (en) 1996-06-05 1996-07-04 Crc For Biopharmaceutical Research Pty Ltd Npy y2 agonists
US6013633A (en) * 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
HUP0202143A3 (en) * 1999-07-28 2003-12-29 Ortho Mcneil Pharm Inc Amine and amide derivatives as ligands for the neuropeptide y y5 receptor pharmaceutical compositions containing them and their use
WO2004066966A2 (en) * 2003-01-17 2004-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Peptide yy analogs
CA2843439A1 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Reversible pegylated drugs
US20090105122A1 (en) 2003-11-25 2009-04-23 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
WO2005080424A2 (en) 2004-02-23 2005-09-01 Rheoscience A/S Peptide yy analogues
US7410949B2 (en) * 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
WO2006091505A2 (en) 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Neuropeptide y receptor agonists
NZ568772A (en) * 2005-12-07 2010-05-28 Hoffmann La Roche Truncated analogs of the peptide pYY3-36 that are neuropeptide-2 receptor-agonists
WO2007085887A1 (en) 2006-01-27 2007-08-02 Pfizer Products Inc. Pyy agonists and uses thereof

Also Published As

Publication number Publication date
US8268784B2 (en) 2012-09-18
NZ568772A (en) 2010-05-28
WO2007065808A3 (en) 2007-08-02
EP1962959B1 (en) 2012-03-14
MA30142B1 (fr) 2009-01-02
US20100137223A1 (en) 2010-06-03
TW200806311A (en) 2008-02-01
ES2381497T3 (es) 2012-05-28
RU2430108C2 (ru) 2011-09-27
JP5000663B2 (ja) 2012-08-15
KR101059602B1 (ko) 2011-08-25
AU2006324076A1 (en) 2007-06-14
US20070135351A1 (en) 2007-06-14
RU2008127265A (ru) 2010-01-20
BRPI0619573A2 (pt) 2011-10-04
JP2009518349A (ja) 2009-05-07
WO2007065808A2 (en) 2007-06-14
EP1962959A2 (en) 2008-09-03
IL191636A0 (en) 2008-12-29
KR20080082672A (ko) 2008-09-11
ATE549350T1 (de) 2012-03-15
TWI321474B (en) 2010-03-11
RU2011105310A (ru) 2012-08-20
ECSP088511A (es) 2008-07-30
NO20082445L (no) 2008-09-03
US7642244B2 (en) 2010-01-05
IL191636A (en) 2012-10-31
CA2630649A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
AR051904A1 (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r)
ECSP088120A (es) Derivados de piridazinona como agonistas del receptorde la hormona tiroidea
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
ECSP088747A (es) Pirazoles como inhibidores de la 11-beta-hsd1
CL2008002768A1 (es) Compuestos derivados de carboxiciclopropil-(bis-fenil-oxamidas); composicion farmaceutica que los contiene; procedimiento para la elaboracion de las composiciones y el uso de los compuestos en el tratamiento de diabetes y trastornos del sncentre otras enfermedades.
GT200600114A (es) Derivados de ciclopropanocarboxamida
ECSP109934A (es) Compuesto - 946
CR20110077A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
UY30267A1 (es) Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
PA8577101A1 (es) Nuevos derivados de glicosido de tiofeno, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
ECSP066855A (es) Derivados de benceno sustituidos por glucopiranosilo, medicamentos que contienen esos compuestos, su aplicación y procedimiento para su preparación
UY28955A1 (es) Nuevos derivados fluoroglicosídicos de pirazoles, medicamentos que contienen estos compuestos, y el empleo de los mismos
ECSP088103A (es) Nuevos derivados de 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones de hiperlipidemia
CR10621A (es) Derivados de adenosina como agonistas del receptor a2a
CR9667A (es) Derivados de benzamida y usos relacionados con los mismos
CR7743A (es) Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf)
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
IN2012DN03042A (es)
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia

Legal Events

Date Code Title Description
FG Grant, registration